| Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: from the STEP 9 randomised clinical trial H Bliddal, H Bays, S Czernichow, JU Hemmingsson, J Hjelmesæth, ... Osteoarthritis and Cartilage 32 (6), 745-746, 2024 | 1 | 2024 |
| Corrigendum to “Obesity pillars roundtable: Body mass index and body composition in black and female individuals. Race-relevant or racist? Sex-relevant or sexist?”[Obesity … HE Bays, S Gonsahn-Bollie, C Younglove, S Wharton Obesity Pillars 10, 2024 | | 2024 |
| Effect of semaglutide 2.4 mg on physical functioning and weight‐and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP … D Rubino, JB Bjorner, N Rathor, AM Sharma, L von Huth Smith, ... Diabetes, Obesity and Metabolism, 2024 | | 2024 |
| Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study S Wharton, T Blevins, L Connery, J Rosenstock, S Raha, KJ Mather, ... Diabetologie und Stoffwechsel 19 (S 01), P12. 01, 2024 | | 2024 |
| Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4) LJ Aronne, N Sattar, DB Horn, HE Bays, S Wharton, WY Lin, NN Ahmad, ... Diabetologie und Stoffwechsel 19 (S 01), P12. 04, 2024 | | 2024 |
| Obesity is South Africa’s new HIV epidemic N Chandiwana, WDF Venter, JM Manne-Goehler, A Wade, CW le Roux, ... South African Medical Journal 114 (3), 1-4, 2024 | 2 | 2024 |
| Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial LJ Aronne, N Sattar, DB Horn, HE Bays, S Wharton, WY Lin, NN Ahmad, ... Jama 331 (1), 38-48, 2024 | 135 | 2024 |
| GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply. S Wharton, M Konig The New England Journal of Medicine 389 (24), 2304-2305, 2023 | | 2023 |
| A scoping review of obesity education interventions for current and prospective medical professionals in Canada TS Nagpal, N Pearce, S Sockalingam, R Hawa, KK Dhaliwal, ... Obesity Pillars 8, 100085, 2023 | | 2023 |
| Once Daily Oral Semaglutide 50 mg Improves Physical Functioning in the OASIS 1 Trial D Rubino, T Holst-Hansen, T Karlsson, K Pietilainen, A Traina, S Wharton, ... OBESITY 31, 75-75, 2023 | | 2023 |
| What Makes You a Competent Doc? N Pearce, J Abraham, T Nagpal, K Dhaliwal, M Forhan, J Furlano, ... OBESITY 31, 268-268, 2023 | | 2023 |
| Economic Burden of Obesity Management: A Retrospective Cohort Study from Ontario, Canada S Wharton, M Luckevich, A Luguzis, M Eberg, A Kukaswadia, C Neish, ... OBESITY 31, 266-267, 2023 | | 2023 |
| Mapping Obesity Education in Canada: What Has Been Done and Where Do We Go from Here? N Pearce, T Nagpal, R Hawa, S Sockalingam, D Lee-Baggley, J Abraham, ... OBESITY 31, 268-268, 2023 | | 2023 |
| Weight Reduction in Patients with Obesity with versus Without T2 Diabetes Treated with Oral Orforglipron J Frias, S Wharton, J Rosenstock, D Robins, K Chen, C Kazda, K Mather, ... OBESITY 31, 279-279, 2023 | | 2023 |
| Characteristics and Obesity Care Pathway for Individuals Living with Obesity in Ontario, Canada S Wharton, A Belloum, A Luguzis, M Eberg, A Kukaswadia, C Neish, ... OBESITY 31, 26-26, 2023 | | 2023 |
| A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity A Strathe, DB Horn, MS Larsen, D Rubino, R Sørrig, MTD Tran, S Wharton, ... Diabetes, Obesity and Metabolism 25 (11), 3171-3180, 2023 | 3 | 2023 |
| Transforming the landscape of obesity education-The Canadian obesity education competencies R Abraham, TS Nagpal, N Pearce, KK Dhaliwal, M El-Hussein, M Forhan, ... Obesity Pillars, 100091, 2023 | 2 | 2023 |
| Review of an international pilot project to adapt the Canadian Adult Obesity Clinical Practice Guideline XR Salas, MAS Contreras, C Breen, Y Preiss, BF Hussey, M Forhan, ... Obesity Pillars, 100090, 2023 | 2 | 2023 |
| Daily oral GLP-1 receptor agonist orforglipron for adults with obesity S Wharton, T Blevins, L Connery, J Rosenstock, S Raha, R Liu, X Ma, ... New England Journal of Medicine 389 (10), 877-888, 2023 | 142 | 2023 |
| Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison CW le Roux, ER Hankosky, D Wang, R Malik, M Yu, A Hickey, H Kan, ... Diabetes, Obesity and Metabolism 25 (9), 2626-2633, 2023 | 12 | 2023 |
